One area that has shown considerable success are monoclonal antibodies. Clinical trials ... and Chief Scientific Officer for Regeneron Pharmaceuticals, to talk about why they decided to invest ...

A single dose of the COVID-19 monoclonal antibody therapy developing Regeneron reduced the risk of contracting the virus by around 82% for up to eight months, according to new trial data.

Indeed, Regeneron believes that the success with Ebola could potentially have ushered in “a new era in which monoclonal antibodies could be used to fight viral diseases and global pandemics.” ...

While Regeneron doesn’t make vaccines specifically, its monoclonal antibody therapy provides a "passive vaccine" effect, temporarily protecting against infections. Dupixent Could Gain 30% More U ...

Currently, the flagship of Regeneron's oncology franchise is Libtayo (cemiplimab-rwlc), which is an anti-PD-1 monoclonal antibody that is approved for the treatment of several types of cancer.

Regeneron is a research-oriented biotech, founded by Schleifer, that had no product on the market for its first 20 years. Today its monoclonal antibodies, particularly Eylea for retinal diseases ...

On February 27, 2008, the Tarrytown, New York-based Regeneron Pharmaceuticals received ... and ACZ 885 (canakinumab), a fully humanized monoclonal antibody directed at IL-1β, from Novartis ...

(RTTNews) - Regeneron Pharmaceuticals (REGN ... an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.

Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline ...

On February 27, 2008, the Tarrytown, New York-based Regeneron Pharmaceuticals received ... and ACZ 885 (canakinumab), a fully humanized monoclonal antibody directed at IL-1β, from Novartis ...